Alphatec Holdings [ATEC] vs Bio-Rad Laboratories [BIO] Detailed Stock Comparison
Alphatec Holdings
NASDAQ
Loading...
Bio-Rad Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Alphatec Holdings wins in 5 metrics, Bio-Rad Laboratories wins in 13 metrics, with 0 ties. Bio-Rad Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Alphatec Holdings | Bio-Rad Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -14.51 | 26.66 | Alphatec Holdings |
| Price-to-Book Ratio | 101.23 | 1.12 | Bio-Rad Laboratories |
| Debt-to-Equity Ratio | 1,238.29 | 19.73 | Bio-Rad Laboratories |
| PEG Ratio | 2.10 | 25.36 | Alphatec Holdings |
| EV/EBITDA | -191.88 | 19.57 | Alphatec Holdings |
| Profit Margin (TTM) | -24.33% | 12.50% | Bio-Rad Laboratories |
| Operating Margin (TTM) | -6.19% | 12.19% | Bio-Rad Laboratories |
| EBITDA Margin (TTM) | N/A | 12.19% | N/A |
| Return on Equity | -376.89% | 4.59% | Bio-Rad Laboratories |
| Return on Assets (TTM) | -7.61% | 1.59% | Bio-Rad Laboratories |
| Free Cash Flow (TTM) | $-137.79M | $266.20M | Bio-Rad Laboratories |
| 1-Year Return | 155.45% | -10.41% | Alphatec Holdings |
| Price-to-Sales Ratio (TTM) | 3.56 | 3.06 | Bio-Rad Laboratories |
| Enterprise Value | $2.88B | $8.03B | Bio-Rad Laboratories |
| EV/Revenue Ratio | 4.22 | 3.14 | Bio-Rad Laboratories |
| Gross Profit Margin (TTM) | 69.58% | 52.99% | Alphatec Holdings |
| Revenue per Share (TTM) | $5 | $92 | Bio-Rad Laboratories |
| Earnings per Share (Diluted) | $-1.13 | $11.08 | Bio-Rad Laboratories |
| Beta (Stock Volatility) | 1.03 | 0.96 | Bio-Rad Laboratories |
News Based Sentiment Overview
Alphatec Holdings
News based Sentiment: mixed
Key Insights:
Alphatec reported strong Q2 results and raised guidance, but a downgrade from Wall Street Zen and insider selling create a mixed picture. While analyst sentiment remains largely positive, the predicted stock decline in September adds another layer of complexity for investors.
Bio-Rad Laboratories
News based Sentiment: positive
Key Insights:
Bio-Rad delivered a significant earnings beat in Q2 2025 and raised its full-year guidance, coupled with strategic acquisitions and increased institutional investment. These developments collectively signal a positive shift in the company's trajectory and strengthen its investment appeal, making it a noteworthy month for investors.
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Alphatec Holdings vs Bio-Rad Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Alphatec Holdings | -0.91% | 3.14% | 6.91% | 31.83% | 43.36% | 81.02% |
| Bio-Rad Laboratories | 2.07% | -0.82% | 8.54% | 34.71% | 13.48% | -9.42% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Alphatec Holdings | 155.45% | 96.64% | 173.33% | 241.67% | -35.84% | -82.74% |
| Bio-Rad Laboratories | -10.41% | -42.00% | -41.50% | 111.69% | 245.13% | 433.75% |
Performance & Financial Health Analysis: Alphatec Holdings vs Bio-Rad Laboratories
| Metric | ATEC | BIO |
|---|---|---|
| Market Information | ||
| Market Cap | $2.45B | $8.14B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 2,249,880 | 271,290 |
| 90 Day Avg. Volume | 2,843,547 | 289,543 |
| Last Close | $16.40 | $295.43 |
| 52 Week Range | $4.88 - $16.70 | $211.43 - $387.99 |
| % from 52W High | -1.80% | -23.86% |
| All-Time High | $105.60 (Jun 12, 2006) | $832.70 (Aug 30, 2021) |
| % from All-Time High | -84.47% | -64.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.28% | 0.02% |
| Quarterly Earnings Growth | 0.27% | 0.02% |
| Financial Health | ||
| Profit Margin (TTM) | -0.24% | 0.13% |
| Operating Margin (TTM) | -0.06% | 0.12% |
| Return on Equity (TTM) | -3.77% | 0.05% |
| Debt to Equity (MRQ) | 1,238.29 | 19.73 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.16 | $263.42 |
| Cash per Share (MRQ) | $1.06 | $50.76 |
| Operating Cash Flow (TTM) | $15.69M | $534.20M |
| Levered Free Cash Flow (TTM) | $21.17M | $223.40M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Alphatec Holdings vs Bio-Rad Laboratories
| Metric | ATEC | BIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -14.51 | 26.66 |
| Forward P/E | -25.23 | 25.36 |
| PEG Ratio | 2.10 | 25.36 |
| Price to Sales (TTM) | 3.56 | 3.06 |
| Price to Book (MRQ) | 101.23 | 1.12 |
| Market Capitalization | ||
| Market Capitalization | $2.45B | $8.14B |
| Enterprise Value | $2.88B | $8.03B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.22 | 3.14 |
| Enterprise to EBITDA | -191.88 | 19.57 |
| Risk & Other Metrics | ||
| Beta | 1.03 | 0.96 |
| Book Value per Share (MRQ) | $0.16 | $263.42 |
Financial Statements Comparison: Alphatec Holdings vs Bio-Rad Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ATEC | BIO |
|---|---|---|
| Revenue/Sales | $169.18M | $585.40M |
| Cost of Goods Sold | $53.18M | $279.40M |
| Gross Profit | $116.00M | $306.00M |
| Research & Development | $16.58M | $73.50M |
| Operating Income (EBIT) | $-31.71M | $23.70M |
| EBITDA | $-10.19M | $98.50M |
| Pre-Tax Income | $-51.97M | $83.40M |
| Income Tax | $-64,000 | $19.40M |
| Net Income (Profit) | $-51.91M | $64.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ATEC | BIO |
|---|---|---|
| Cash & Equivalents | $153.24M | $521.40M |
| Total Current Assets | $434.89M | $3.04B |
| Total Current Liabilities | $157.87M | $506.60M |
| Long-Term Debt | $572.40M | $1.33B |
| Total Shareholders Equity | $-85.94M | $6.68B |
| Retained Earnings | $-1.33B | $7.48B |
| Property, Plant & Equipment | $320.90M | $681.70M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ATEC | BIO |
|---|---|---|
| Operating Cash Flow | $-23.48M | $156.00M |
| Capital Expenditures | $-9.93M | $-34.40M |
| Free Cash Flow | $-16.65M | $95.50M |
| Debt Repayment | $-321.03M | $-100,000 |
| Common Stock Repurchase | $-3.00M | $-101.90M |
Short Interest & Institutional Ownership Analysis
| Metric | ATEC | BIO |
|---|---|---|
| Shares Short | 12.37M | 1.00M |
| Short Ratio | 4.47 | 3.20 |
| Short % of Float | 0.10% | 0.05% |
| Average Daily Volume (10 Day) | 2,249,880 | 271,290 |
| Average Daily Volume (90 Day) | 2,843,547 | 289,543 |
| Shares Outstanding | 144.13M | 28.01M |
| Float Shares | 116.32M | 18.50M |
| % Held by Insiders | 0.21% | 0.16% |
| % Held by Institutions | 0.69% | 0.89% |
Dividend Analysis & Yield Comparison: Alphatec Holdings vs Bio-Rad Laboratories
| Metric | ATEC | BIO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |